

Vir Biotechnology, Inc. (VIR)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001706431

[illegible]

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 23, 2026

-Government Regulation and Product Approval-Expedited Development and Review Programs" and "Part I, Item 1. Business-Government Regulation and Product Approval-Foreign Regulation" in this Annual Report on Form 10-K. Clinical product development involves a lengthy and expensive process. We may incur additional costs and encounter substantial delays or difficulties in our clinical studies. Before obtaining marketing approval for the sale of our product candidates, we must complete preclinical

development and conduct extensive clinical studies to demonstrate the safety and efficacy of our product candidates in humans.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 68.0						
Gross profitability		6.8%	32.2%	80.9	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(3.8%)	(6.6%)	67.3	811	2025-12-31
Gross margin stability, five years		3.3 pts	2.8 pts	55.8	243	2025-12-31
Solvency, sleeve percentile 27.9						
Twelve-month failure probability		0.02%	0.07%	9.7	248	2026-06-30
Altman Z double-prime		(0.97)	(0.31)	41.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		5.54x	2.96x	32.9	839	2025-12-31
Growth and financing, sleeve percentile 73.4						
Revenue growth, three-year compound		(65.1%)	10.0%	97.3	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		(29.0%)	2.1%	92.5	704	2025-12-31
Net share issuance, one year		1.7%	2.5%	30.3	634	2026-02-17

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
269	Bausch Health Companies Inc. (BHC)	72.4	D	
270	3M Co. (MMM)	72.7	D	
271	Elanco Animal Health Inc. (ELAN)	73.0	D	
272	ICU Medical Inc/De (ICUI)	73.2	D	
273	Butterfly Network, Inc. (BFLY)	73.5	D	
274	Vir Biotechnology, Inc. (VIR) <	73.8	D	
275	Viatis Inc. (VTRS)	74.1	D	
276	Precision Optics Corporation, Inc. (POCI)	74.3	D	dilution,
				fortress
				balance sheet
277	Retractable Technologies Inc. (RVP)	74.6	D	fortress
				balance sheet
278	NutriBand Inc. (NTRB)	75.0	D	fortress
				balance sheet
279	NutriBand Inc. (NTRBW)	75.0	D	fortress
				balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	91.6%	8.0%	86
Distance from 52-week high	(5.6%)	(31.4%)	92
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(21.1%)	(1.0%)	22
Book value to price	0.52	0.28	71
Sales to price	0.04	0.31	12
Composite equity issuance, five years	28.0%	20.3%	56
Relative strength against the sector, log excess return	0.44	(0.14)	86

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$278.7M
Operating cash flow, four quarters	-\$202.5M
Months of runway	16.5
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$18.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$68.6M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
2	cost of revenue	us-gaap:CostOfRevenue	\$26,000	2025-12-31	2026-02-23	10-K	0001628280-26-010749
3	assets	us-gaap:Assets	\$1.0B	2025-12-31	2026-02-23	10-K	0001628280-26-010749

4	net income	us-gaap:NetIncomeLoss	-\$438.0M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$391.8M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
6	assets	us-gaap:Assets	\$1.4B	2024-12-31	2026-02-23	10-K	0001628280-26-010749
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$74.2M	2024-12-31	2026-02-23	10-K	0001628280-26-010749
8	cost of revenue	us-gaap:CostOfRevenue	\$845,000	2024-12-31	2026-02-23	10-K	0001628280-26-010749
9	revenue	us-gaap:Revenues	\$86.2M	2023-12-31	2026-02-23	10-K	0001628280-26-010749
10	cost of revenue	us-gaap:CostOfRevenue	\$2.8M	2023-12-31	2026-02-23	10-K	0001628280-26-010749
11	revenue	us-gaap:Revenues	\$1.6B	2022-12-31	2025-02-27	10-K	0001628280-25-008245
12	cost of revenue	us-gaap:CostOfRevenue	\$146.3M	2022-12-31	2025-02-27	10-K	0001628280-25-008245
13	revenue	us-gaap:Revenues	\$1.1B	2021-12-31	2024-02-26	10-K	0001628280-24-006852
14	cost of revenue	us-gaap:CostOfRevenue	\$65.9M	2021-12-31	2024-02-26	10-K	0001628280-24-006852
15	current assets	us-gaap:AssetsCurrent	\$514.1M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
16	current liabilities	us-gaap:LiabilitiesCurrent	\$92.8M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.2B	2025-12-31	2026-02-23	10-K	0001628280-26-010749
18	operating income	us-gaap:OperatingIncomeLoss	-\$479.3M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
19	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterests	\$765.3M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
20	liabilities	us-gaap:Liabilities	\$237.5M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.8M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$446.4M	2024-12-31	2026-02-23	10-K	0001628280-26-010749
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.3M	2024-12-31	2026-02-23	10-K	0001628280-26-010749
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$778.8M	2023-12-31	2026-02-23	10-K	0001628280-26-010749
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$21.6M	2023-12-31	2026-02-23	10-K	0001628280-26-010749
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.7B	2022-12-31	2025-02-27	10-K	0001628280-25-008245
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$68.0M	2022-12-31	2025-02-27	10-K	0001628280-25-008245
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$11.7M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	-\$477.8M	2025-12-31	2026-02-23	10-K	0001628280-26-010749
30	income tax	us-gaap:IncomeTaxExpenseBenefit	\$217,000	2025-12-31	2026-02-23	10-K	0001628280-26-010749
31	current assets	us-gaap:AssetsCurrent	\$1.0B	2024-12-31	2026-02-23	10-K	0001628280-26-010749
32	current liabilities	us-gaap:LiabilitiesCurrent	\$119.7M	2024-12-31	2026-02-23	10-K	0001628280-26-010749
33	assets	us-gaap:Assets	\$1.9B	2023-12-31	2025-02-27	10-K	0001628280-25-008245
34	assets	us-gaap:Assets	\$2.8B	2022-12-31	2024-02-26	10-K	0001628280-24-006852
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	139,517,278	2026-02-17	2026-02-23	10-K	0001628280-26-010749
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	137,143,286	2025-02-20	2025-02-27	10-K	0001628280-25-008245